孟鲁司特钠联合布地奈德治疗哮喘的疗效分析

Analysis on the Curative Effect of Montelukast Sodium Combined with Budesonide in the Treatment of Asthma

目的分析孟鲁司特钠联合布地奈德治疗哮喘的疗效。方法选择2016年2月至2018年6月我院收治的支气管哮喘患者128例为研究对象,随机分为两组各64例。对照组给予布地奈德气雾剂治疗,研究组在对照组基础上给予孟鲁司特钠咀嚼片治疗。比较两组的疗效及不良反应,以及治疗前后的一秒用力呼气容积占预计值百分比(FEV1%)、一秒用力呼气容积比用力肺活量(FEV1/FVC)、呼气流速峰值占预计值百分比(PEF%)等肺功能指标。结果研究组的总控制率为93.8%,显著高于对照组的78.1%(P <0.05);治疗后,研究组的FEV1%、 FEV1/FVC、 PEF%均显著高于对照组(P <0.05);两组的不良反应发生率无统计学差异(P>0.05)。结论孟鲁司特钠联合布地奈德治疗哮喘的效果显著,可快速缓解患者的症状,改善肺功能,且安全性较高。

Objective To analyze the curative effect of montelukast sodium combined with budesonide in the treatment of asthma. Methods A total of 128 patients with bronchial asthma admitted to our hospital from February 2016 to June 2018 were selected as research objects, and randomly divided into two groups, with 64 cases in each group. The control group was treated with budesonide aerosol, and the study group was treated with montelukast sodium chewable tablets combined with budesonide aerosol. The efficacy, adverse reactions, and lung function indicators including forced expiratory volume in one second as a percentage of predicted value (FEV1%), forced expiratory volume in one second as a percentage of forced vital capacity (FEV1/FVC), and peak expiratory flow rate as a percentage of predicted value (PEF%) before and after treatment were compared between two groups. Results The total control rate of the study group was 93.8%, significantly higher than 78.1% of the control group (P <0.05). After treatment, the FEV1%, FEV1/FVC and PEF% of the study group were significantly higher than those of the control group (P <0.05). No statistical difference was found between the two groups in the incidence of adverse reactions (P >0.05). Conclusions Montelukast sodium combined with budesonide has remarkable effect and high safety in the treatment of asthma, which can rapidly relieve patients' symptoms, and improve lung function.